1. Monosodium urate crystal depletion and bone erosion remodeling during pegloticase treatment in patients with uncontrolled gout: Exploratory dual-energy computed tomography findings from MIRROR RCT.
- Author
-
Dalbeth, Nicola, Botson, John, Saag, Kenneth, Kumar, Ada, Padnick-Silver, Lissa, LaMoreaux, Brian, and Becce, Fabio
- Subjects
- *
COMPUTED tomography , *BONE remodeling , *GOUT , *DUAL energy CT (Tomography) , *BONE growth - Abstract
• Dual-energy CT (DECT) can image and quantify urate deposition and bone erosions. • Intensive urate-lowering with pegloticase led to rapid urate depletion on DECT. • Deposited urate depletion was fastest during pegloticase treatment. • With urate depletion, bone remodeling occurred within 1 year in most erosions. Monosodium-urate (MSU) crystal deposits can be visualized and quantified with dual-energy CT (DECT). Pegloticase lowers serum urate (SU) in uncontrolled gout patients, with methotrexate (MTX) co-therapy recommended to increase SU-lowering response rate and decrease infusion reaction risk. The literature on serial DECT-imaging during pegloticase + MTX co-therapy is sparse, with only 2 prior cases of rapid MSU deposition depletion with subsequent bone-erosion remodeling reported from a small open-label trial. Here, we report DECT findings during pegloticase treatment in a larger number of patients from a randomized controlled trial to confirm bone-erosion remodeling that follows MSU depletion with pegloticase. The influence of length-of-therapy is also explored. Patients received pegloticase (8 mg every 2 weeks) + MTX (15 mg/week orally) or pegloticase + placebo (PBO) during the MIRROR RCT trial. A subset underwent DECT-imaging on Day1 (first pegloticase infusion) and at Weeks 14, 24, and 52. Patients with paired baseline-Week 52 images were included. Imaged regions with baseline MSU-crystal volume (V MSU) < 0.5 cm3 were excluded to minimize artifact contributions. V MSU and bone-erosion remodeling were assessed. Eight patients (6 MTX, 2 PBO) were included. Included patients had received 52 weeks (5 MTX), 42 weeks (1 PBO), and 6 weeks (1 MTX, 1 PBO) of pegloticase therapy. Patients who prematurely discontinued pegloticase maintained SU < 6 mg/dL on allopurinol (n = 2)/febuxostat (n = 1). At Week 52, V MSU had markedly decreased in both the pegloticase + MTX and pegloticase + PBO treatment groups, with faster depletion during pegloticase therapy. Bone-erosion remodeling was observed in 29/42 (69%) evaluated erosions: 29 (69%) size decrease, 4 (9.5%) recortication, 3 (7.1%) new bone formation. Rapid V MSU depletion during pegloticase therapy was observed with concomitant bone remodeling within 1 year. Following pegloticase discontinuation, V MSU reduction slowed or stopped even when SU was maintained < 6 mg/dL with oral ULT. NCT03994731. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF